The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Outlook
The UK Health and Medical products Regulatory Agency has granted 4D expedited acceptance to start a Phase II study of MRx-4DP0004 in patients with COVID-19. The management has prioritised allocation of resources and capital to main programmes such as oncology and launch of Phase II clinical trial of an orally administered immunomodulatory LBP in COVID-19 in Q2 FY20. Moreover, the current study of Company stated that the high mortality rate of COVID-19 could be due to hyper-inflammatory response and cytokine storm syndrome caused by uncontrolled activation of the immune system. Hence, targeted immunomodulation might be proven beneficial for patients.
Breakthrough Clinical Trials Launched by 2 LSE Stocks: Synairgen PLC and 4D Pharma Group PLC....
Established in 2014, 4D Pharma Group PLC is a developer of Live Biotherapeutics and a MicroRx® (a proprietary platform). The Company has the following study in progress - BLAUTIX®, MRx0518, KEYTRUDA®, MRx-4DP0004. The Group has also signed a research partnership with Merck & Co., Inc. (MSD) to discover Live Biotherapeutics for vaccines. The Company is listed on the FTSE AIM All-Share index and was admitted to the London Stock Exchange (LSE) on 18th February 2014.
Recent Significant Developments of 2020
21st May 2020: Thomas Engelen has resigned from his position of Non-executive Director, which will come in effect from 20th May 2020.
11th May 2020: The clinical study of Phase I/II (PART A) of MRx0518, in combination with Keytruda® has been completed.
20th April 2020: The Company’s MRx-4DP0004 (phase II trial) has been approved for commencement by the MHRA (Medicines and Healthcare products Regulatory Agency).
Financial Highlights - Adding Extensive Experience in Innovative Drug Development
On 26th May 2020, the Company provided the final results for the year ended 31 December 2019, with a successful year in which the Group had entered collaborations with new partners and made great progress in the clinic across multiple programmes. Additional points are stated below:
Net assets for the financial year 2019 stood at GBP 22.3 million as compared with the previous year (2018: GBP 45.8 million).
Including cash on deposit, the cash and cash equivalents decreased to GBP 3.8 million against the last year (2018: GBP 26.2 million).
Total comprehensive loss after tax for the financial year 2019 was GBP 23.7 million (2018: GBP 24.3 million).
In FY19, the adjusted loss per share increased to 40.81 pence (FY18: 36.17 pence), while basic and diluted loss per share stood at 36.75 pence (FY18: 36.17 pence).
Some operational highlights: positive early signals for MRx0518 in combination with Keytruda®; entered a research collaboration and options contract with MSD, which include a commitment to equity investment in the Company by MSD; launched Phase I/II study to assess safety and efficacy of MRx-4DP0004 in addition to standard maintenance therapy in poorly controlled asthma
Launched the third trial of MRx0518 in early January 2020.
After the period end, in February 2020, the Company accomplished a fundraise through the placing and a subscription for new ordinary shares with and by certain current & new investors, to raise aggregate gross proceeds of GBP 22 million.